MedPath

Effects omega-3 fatty acid supplementation in the treatment of diabetes

Phase 2
Conditions
Diabetic nephropathy.
Insulin-dependent diabetes mellitus
Registration Number
IRCT201502255623N36
Lead Sponsor
Kashan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients with diabetic nephropathy aged 45 to 85 years.
Proteinuria level>0.3 g/24 h, with or without elevation of serum creatinine levels

Exclusion Criteria

The intake of omega-3 fatty acid supplements within 3 months
Patients with uncontrolled diabetes
The current use of warfarin
Malignancy and/or liver cirrhosis.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath